Skip to main content
SpringerLink
Log in

Tumor Regression and Autoimmunity in CytotoxicT Lymphocyte–Associated Antigen 4 Blockade–Treated Patients

  • Editorial
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105–16

    PubMed  CAS  Google Scholar 

  2. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14:2410–1

    PubMed  CAS  Google Scholar 

  3. Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 2001;19:3194–202

    PubMed  CAS  Google Scholar 

  4. O’Day SJ, Boasberg PD, Piro L, et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002;8:2775–81

    PubMed  CAS  Google Scholar 

  5. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte–associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (in press)

  6. Linsley PS, Brady W, Urnes M, Grosmaire MLS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561–9

    Article  PubMed  CAS  Google Scholar 

  7. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712–7

    Article  PubMed  CAS  Google Scholar 

  8. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372–7

    Article  PubMed  CAS  Google Scholar 

  9. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741–50

    PubMed  CAS  Google Scholar 

  10. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role for CTLA-4. Immunity 1995;3:541–6

    Article  PubMed  CAS  Google Scholar 

  11. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;2671:1734–6

    Google Scholar 

  12. Lute KD, May KF, Lu P, et al. Human CTLA-4-knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 2005 (in press)

Download references

Author information

Authors and Affiliations

  1. Norris Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California, 90033

    Jeffrey S. Weber MD, PhD

Authors
  1. Jeffrey S. Weber MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey S. Weber MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weber, J.S. Tumor Regression and Autoimmunity in CytotoxicT Lymphocyte–Associated Antigen 4 Blockade–Treated Patients. Ann Surg Oncol 12, 957–959 (2005). https://doi.org/10.1245/ASO.2005.08.917

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2005.08.917

Keywords

Search

Navigation